Among upstream regulators predicted to be inhibited in NASH, apolipoprotein E (Apoe), SREBF chaperone (Scap), and paraoxonase 1 (Pon1) are associated with cholesterol metabolism (Table 3 (2)). The gene discussed is PON1; the disease is metabolic dysfunction-associated steatohepatitis.